Newron's Shareholders with an overwhelming majority vote in favour of NeuroNova acquisition Milan, Italy - 5 December 2012 - Newron Pharmaceuticals S.p.A. ("Newron", SIX: NWRN), a research and development company focused on Central Nervous System (CNS) and pain therapies, announces that at its Shareholder's Meeting held today, 5 December 2012, in Zurich, all motions on the agenda were accepted: *Increase in the share capital, to be subscribed via contribution in kind of shares of NeuroNova AB, a condition precedent to the acquisition of NeuroNova AB; *Revocation of the increase in the Company's share capital resolved by the shareholders' meeting on 28 June 2012; *Amendment of the number of the members of the Board of Directors from 6 up to 7, appointment of a director as proposed by NeuroNova AB current shareholders and determination of his relevant remuneration. The shareholders elected Jakob Lindberg to the Board of Directors. Jakob Lindberg joined the Investor Growth Capital Europe team in 2005. He focuses primarily on investments in the healthcare sector.* At the Shareholders's meeting 3,767,962 shares of the company's total capital of 8,796,332 shares, or 40.84%, were represented. The acquisition was approved by 100% of the represented shares. Rolf Stahel, Chairman of Newron, said: "We are grateful to our shareholders for voting in favour of all motions. The revised agreement to acquire NeuroNova experienced strong support both from institutional and retail shareholders demonstrating clearly that there is trust and support in Newron's strategy to broaden its development pipeline, its cash position and shareholder base." Stefan Weber, CEO of Newron, said: "Safinamide stays our main priority as it is our key value driver. Our team is working to expedite the global filing of the compound, together with our partners, Zambon and Meiji. With this acquisition we can now broaden our pipeline. The new funds raised in August and those available through the acquisition of NeuroNova will allow us to develop other novel compounds in our pipeline to the next value creation point, including the two NeuroNova projects. We are truly excited by the trust that our shareholders have put in management's strategy. The entire management looks forward to combining NeuroNova's highly innovative pipeline products with Newron's demonstrated developmental and regulatory expertise." * In addition, Jakob Lindberg is the CEO of Oncopeptides, a pharmaceutical company working to develop more effective chemotherapeutic treatments for cancer. Prior to joining Investor Growth Capital, he worked at McKinsey & Company and was the co-founder and CEO of Cellectricon, a Swedish company developing functional, cell-based screening devices for drug discovery. Jakob Lindberg is a licensed Swedish physician with an M.D. and Medical Licentiate thesis from the Karolinska Institute, and a B.A. in Finance from Stockholm University. About Newron Pharmaceuticals Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Phase III trials of safinamide for the treatment of Parkinson's disease (PD) have been completed earlier in 2012. Based on the phase III results of safinamide, Newron is working to expedite the global filing of the compound, together with its partners. Zambon Group has the rights to commercialise safinamide globally, excluding Japan and other key Asian territories, and Meiji Seika has the rights to develop and commercialise safinamide in Japan and other key Asian territories. Newron's additional projects are primarily addressed towards highly promising rare diseases and are at various stages of preclinical and clinical development, including sarizotan for Rett's syndrome, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia. www.newron.com For more information, contact: Media Investors and analysts Italy Stefan Weber - CEO Phone: +39 02 6103 46 26 E-mail: firstname.lastname@example.org UK/Global media Stefan Weber - CEO Julia Phillips Phone: +39 02 6103 46 30 FTI Consulting E-mail: email@example.com Phone: +44 (0) 20 7269 7187 Switzerland Martin Meier-Pfister IRF Communications Phone: +41 43 244 81 40 Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Media Release (PDF) Provider Channel Contact Tensid Ltd., Switzerland newsbox.ch Provider/Channel related enquiries www.tensid.ch www.newsbox.ch firstname.lastname@example.org +41 41 763 00 50
Newron's Shareholders with an overwhelming majority vote in favo
Press spacebar to pause and continue. Press esc to stop.